Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Other Accumulated Expenses (2023 - 2025)

Cytosorbents filings provide 3 years of Other Accumulated Expenses readings, the most recent being $965000.0 for Q2 2025.

  • On a quarterly basis, Other Accumulated Expenses changed N/A to $965000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was $965000.0, a N/A change, with the full-year FY2024 number at $812000.0, down 18.11% from a year prior.
  • Other Accumulated Expenses hit $965000.0 in Q2 2025 for Cytosorbents, up from $796925.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $991545.0 in Q4 2023 to a low of $796925.0 in Q1 2025.
  • Median Other Accumulated Expenses over the past 3 years was $888500.0 (2024), compared with a mean of $891367.5.
  • The widest YoY moves for Other Accumulated Expenses: up 18.11% in 2024, down 18.11% in 2024.
  • Cytosorbents' Other Accumulated Expenses stood at $991545.0 in 2023, then dropped by 18.11% to $812000.0 in 2024, then grew by 18.84% to $965000.0 in 2025.
  • The last three reported values for Other Accumulated Expenses were $965000.0 (Q2 2025), $796925.0 (Q1 2025), and $812000.0 (Q4 2024) per Business Quant data.